Suppr超能文献

羟基脲治疗不可切除的生长缓慢的脑膜瘤。

Non-resectable slow-growing meningiomas treated by hydroxyurea.

作者信息

Loven David, Hardoff Ruth, Sever Zvi Bar, Steinmetz Adam P, Gornish Michael, Rappaport Zvi H, Fenig Eyal, Ram Zvi, Sulkes Aaron

机构信息

Institute of Oncology, Ha'Emek Medical Center, Afula, Israel.

出版信息

J Neurooncol. 2004 Mar-Apr;67(1-2):221-6. doi: 10.1023/b:neon.0000021827.85754.8e.

Abstract

PURPOSE

To test the benefit of hydroxyurea in the treatment of recurrent and non-resectable slow-growing meningiomas.

METHODS

Twelve patients with regrowing non-malignant meningiomas, were enrolled for a protocol of 2 years with continuous chemotherapy with hydroxyurea, 20 mg/kg/day. Response to treatment was evaluated both clinically and by diagnostic imaging using computed tomography (CT) and 201-Thallium single photon emission CT. One minimal response was documented by CT, accompanied by clinical stabilization. Nine patients showed progressive disease, at least by one imaging procedure, with a median time to progression of 13 months (range 4-24). Two other patients were not available for response due to early removal from the study, following abrupt manifestation of grades 3-4 hematological toxicity.

CONCLUSION

In this series hydroxyurea has not shown effectiveness in the treatment of non-resectable slow-growing meningiomas: neither for achieving response, nor for arresting disease progression.

摘要

目的

测试羟基脲在治疗复发性和不可切除的生长缓慢的脑膜瘤中的疗效。

方法

12例非恶性脑膜瘤复发患者参加了一项为期2年的方案,持续使用羟基脲化疗,剂量为20mg/kg/天。通过临床评估以及使用计算机断层扫描(CT)和铊-201单光子发射CT进行诊断成像来评估治疗反应。CT记录到1例最小反应,伴有临床病情稳定。9例患者至少通过一种成像检查显示疾病进展,进展的中位时间为13个月(范围4-24个月)。另外2例患者因在出现3-4级血液学毒性后被提前退出研究而无法评估反应。

结论

在本系列研究中,羟基脲在治疗不可切除的生长缓慢的脑膜瘤方面未显示出有效性:既未实现反应,也未阻止疾病进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验